Leflunomid Pharmathen

Leflunomide, the active ingredient in Leflunomid Pharmathen, is an immunomodulatory agent presented as an oral tablet for oral use. It is employed to treat inflammatory joint diseases such as rheumatoid arthritis and psoriatic arthritis in adult patients. It is indicated for adult patients with moderate to severe disease activity.

GNH USA supplies Leflunomid Pharmathen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets.

Leflunomide, a disease-modifying antirheumatic drug (DMARD), modulates immune pathways involved in inflammatory arthritis.

- Rheumatoid arthritis: reduces joint inflammation, pain, and slows radiographic progression. - Psoriatic arthritis: improves skin lesions and joint symptoms, decreasing disease activity. - Rheumatoid arthritis refractory to conventional DMARDs: provides an alternative therapeutic option when standard treatments fail.

Leflunomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea - Nausea - Elevated liver enzymes

Serious or Rare Side Effects: - Severe liver injury or hepatitis - Bone marrow suppression leading to anemia or leukopenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor relevant parameters throughout treatment.

- Pregnancy: contraindicated (Category X); avoid use in pregnant women. - Liver function: monitor transaminases before and during therapy. - Hematology: perform regular complete blood counts to detect cytopenias. - Infections: postpone initiation in patients with active serious infections. - Drug interactions: avoid concomitant use with teratogenic agents and live vaccines. - Store at ambient temperature: keep in original container, protect from moisture and light.

Leflunomide can interact with several medicines, requiring careful assessment of concomitant use.

Major Interactions (Avoid): - Methotrexate: increased hepatotoxicity risk. - Warfarin: enhanced anticoagulant effect. - Live vaccines: risk of severe infection.

Moderate Interactions (Monitor Closely): - NSAIDs: increased gastrointestinal adverse effects. - Oral contraceptives: possible reduction in contraceptive efficacy.